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Abstract: This study investigated the possible association of the interleukin-1 beta (IL-1β) 
C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)n 
variable number of tandem repeats (VNTR) polymorphism with antidepressant response to 
paroxetine and mirtazapine treatment. The study group consisted of 101 patients suffering from 
DSM-IV major depression participating in a randomized double-blind controlled clinical trial. 
Patients homozygous for the IL-1β-511T allele had a signiﬁ  cantly faster and more pronounced 
response to paroxetine treatment than IL-1β-511C allele carriers. No association was found 
for the IL-1β C-511T polymorphism with mirtazapine treatment response. The IL-1Ra VNTR 
showed neither an association with paroxetine nor with mirtazapine treatment response. Our 
results provide further suggestive evidence that time course of response and antidepressant 
efﬁ  cacy of paroxetine, but not of mirtazapine, is inﬂ  uenced in a clinically relevant manner by 
the IL-1β C-511T gene variant. Our data do not support the hypothesis that the IL-1Ra (86bp)n 
VNTR affects antidepressant treatment response to paroxetine or mirtazapine. An independent 
replication of our ﬁ  nding is needed. If replicated, the IL-1β C-511T promoter polymorphism 
could be considered useful for prospective conﬁ  rmatory pharmacogenetic trials in patients with 
major depression.
Keywords: major depression, antidepressive agents, treatment outcome, interleukin-1 beta, 
interleukin-1 receptor antagonist, genetic polymorphisms
Introduction
A growing body of evidence supports the hypothesis that cytokine activity is involved 
in the etiology and pathophysiology of behavioral and somatic symptoms of major 
depression (MD) (Hayley et al 2005; Raison et al 2006). Among the cytokines, ani-
mal and clinical studies have demonstrated that interleukin 1beta (IL-1β) may have 
a key role in major depression and in the effects of antidepressant treatment (Licinio 
and Wong 1999; Kenis and Maes 2002). In MD patients, IL-1β levels have been 
investigated under several experimental conditions. Some of the results showed an 
increase in the blood or cerebrospinal ﬂ  uid (CSF) of depressed patients (Levine et al 
1999; Anisman et al 1999; Owen et al 2001; Thomas et al 2005). It was also reported 
that CSF IL-1β levels were correlated with depression subtype (Kaestner et al 2005), 
depression severity (Levine et al 1999), age of onset, and duration of illness (Anisman 
et al 1999). However, other studies have found that the IL-1β levels were unchanged 
(Brambilla and Maggioni 1998; Kagaya et al 2001), and not correlated with the sever-
ity of depression (Rothermund et al 2001). To elucidate the complex neurobiological 
effects of IL-1 in brain, several investigations have been performed in animal models. Neuropsychiatric Disease and Treatment 2008:4(1) 270
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Systemic administration of IL-1 in rats increased dopamine 
(DA), norepinephrine (NE), and serotonin (5-HT) activities in 
hypothalamic nuclei, nucleus accumbens, and limbic regions 
including the hippocampus (Merali et al 1997; Anisman and 
Merali 1999; Dunn et al 1999; Song et al 1999). Increases in 
hippocampal extracellular 5-HT levels have also been found 
following intracerebroventricular (i.c.v.) administration of 
IL-1β in rats (Linthorst et al 1995). IL-1β has been shown to 
up-regulate hippocampal expression of the 5-HT transporter 
(Ramamoorthy et al 1995) and to activate neuronal 5-HT 
(Zhu et al 2006).
The action of IL-1β is regulated by a complex network 
of molecules including the anti-inﬂ  ammmtory interleukin-
1 receptor antagonist (IL-1Ra) (Anisman 2004; Licinio 
et al 2007), which represents a naturally occuring endog-
enous antagonist of IL-1 actions. Several studies support a 
neuroprotective function of IL-1Ra (Licinio and Wong 1999), 
which is constitutively expressed in brain (Licinio et al 2007). 
Additionally, i.c.v. administrated IL-1Ra prevented the 
development of behavioral deﬁ  cits in the learned helplessness 
model of depression (Maier and Watkins 1995). In patients 
with MD, IL-1Ra serum levels were found to be elevated 
compared to normal controls (Kubera et al 2000).
Several studies addressed the effects of antidepres-
sive treamtent on cytokine secretion and plasma levels in 
depressed patients, indicating a normalization of cytokine 
plasma levels and cytokine production after antidepressant 
treatment (Castanon et al 2002; Kenis and Maes 2002). How-
ever, in brain the chronic administration of antidepressants 
led to an increased expression of IL-1Ra mRNA and IL-1β 
mRNA (Suzuki et al 1996).
Taking into account the existing evidence for the close 
relation between IL-1β, IL-1Ra and MD, the genes encod-
ing IL-1β and IL-1Ra can be considered candidate genes for 
antidepressant treatment response in MD. Both genes map 
on chromosome 2 in the region q13-q21 (Nicklin et al 1994). 
A single nucleotide polymorphism (C/T) has been identiﬁ  ed 
in the 5′- regulatory region (position -511) of the IL-1β gene 
(di Giovine et al 1992). Pociot and colleagues (1992) dem-
onstrated that individuals homozygous for the IL-1β-511T 
allele secreted signiﬁ  cantly more IL-1β than heterozygous 
individuals, who secreted signiﬁ  cantly more than IL-1β-
511C homozygous individuals. Intron 2 of the IL-1Ra gene 
contains a penta-allelic variable number of tandem repeats 
(VNTR) of a 86bp sequence (ﬁ  ve alleles comprising between 
two and six repeats). In the general population, the IL-1Ra 
allele 1 (86bp)4 is more common (0.74) than allele 2 (86bp)2 
(0.21); the remaining alleles occur at a combined frequency 
of less than 5% (Tarlow et al 1993). Functionally, allele 2 
was associated with an increased plasma level of IL-1Ra in 
Finnish healthy volunteers (Hurme and Santtila 1998).
Paroxetine is widely and successfully used in the treat-
ment of MD. Like all SSRI, it exerts its antidepressant 
effects mainly through inhibition of the serotonin transporter 
(5-HTT). Yu and colleagues (2003) reported that depressed 
patients homozygous for the -511T allele had a more favor-
able ﬂ  uoxetine treatment response than -511C allele carriers, 
so that one could hypothesize a similar effect in our sample of 
paroxetine-treated patients. Mirtazapine is an antidepressant 
that is believed to antagonize central α2-receptors located on 
both noradrenergic and serotonergic neurons. As a result, 
mirtazapine enhances both the neurotransmission of 5-HT 
and NE. Additionally, mirtazapine inhibits 5-HT2A, 5-HT2C 
and 5-HT3 receptors, thereby focusing the enhanced seroto-
nergic neurotransmission on 5-HT1A receptors (Anttila and 
Leinonen 2001). To our knowledge, there is no previous 
report on an investigation of IL-1 gene complex variants and 
mirtazapine treatment response.
The aim of the present study, which is a part of a more 
comprehensive clinical genetics project on treatment response 
in depression (Szegedi et al 2005; Tadic ´ et al 2007a, 2007b), 
was to investigate the possible effect of the IL-1β C-511T 
and IL-1Ra (86bp)n intron 2 polymorphism on the outcome 
of antidepressant response to paroxetine and mirtazapine 
treatment in patients with MD.
Methodology
Patients
A total of 269 outpatients were enrolled in a multicenter, 
randomized, double-blind comparison of paroxetine and 
mirtazapine conducted at 50 centers in Germany. Of these 
patients, 116 gave written informed consent for the collection 
of blood samples for DNA genotyping and the analyses of 
possible associations between genotypes and clinical data 
(eg, response to treatment). All study components have been 
approved by the local ethics committees.
A more detailed description of the recruitment proce-
dure, treatment schedule, and clinical assessments has been 
reported in a previous paper (Benkert et al 2000). Brieﬂ  y, 
females and males, aged from 18 to 70 years suffering from 
acute major depressive episode (MDE) with a sum score  18 
points on the 17-item version of the Hamilton Rating Scale 
for Depression (HAMD-17) at the start and end of a placebo 
washout period were eligible for the study. Diagnosis of MDE 
according to DSM-IV criteria was assigned by eleven clini-
cally experienced research assistants, who underwent several Neuropsychiatric Disease and Treatment 2008:4(1) 271
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rater trainings prior to the start of the study. Exclusion criteria 
were the lack of response to at least two adequate antidepres-
sant treatments during the current depressive episode, current 
episode’s duration more than twelve months, more than three 
previous episodes that did not respond to adequate treatment, 
a reduction of  25% in the HAMD-17 sum score during 
placebo washout period, suicide risk deﬁ  ned as a score of four 
to six on item ten of the Montgomery-Åsberg-Depression-
Rating-Scale (MADRS), history of bipolar affective disorder, 
depressive disorder not otherwise speciﬁ  ed, panic disorder 
(with or without agoraphobia), agoraphobia without a history 
of panic disorder, schizophrenia, organic mental disorder, 
eating disorder, speciﬁ  c phobia, social phobia, or generalized 
anxiety disorder.
After a 3- to 7-day washout period, patients were 
randomly assigned to either mirtazapine or paroxetine 
treatment for six weeks. Mirtazapine was ﬁ  rst administered 
at 15 mg (days 1 and 2), from day 3 onward at 30 mg/day; 
after 2 weeks, an increased dose of 45 mg/day was given 
to nonresponders, deﬁ  ned by Clinical Global Impressions 
scale (CGI) ratings in the therapeutic effect item of “slight” 
or “unchanged/worsened” and no “outweighs therapeutic 
efﬁ  cacy” ratings in the tolerability item. Paroxetine dose 
was 20 mg/day and could be increased to 40 mg/day after 
2 weeks in nonresponders according to the same pre-speciﬁ  ed 
CGI criterion. No concomitant psychotropic treatment was 
allowed during the study. All patients were assessed at 
baseline (day 0), and on days 7, 14, 21, 28, and 42 of active 
treatment using the HAMD-17.
DNA analysis
Genotyping was performed blind to treatment and clinical 
course of the illness. Genomic DNA was prepared from 
10 ml blood using the Quiagen Maxi DNA Extraction Kit 
(Quiagen, Hilden, Germany). Genotyping of the C-511T 
variant of the IL-1β gene (dbSNP: rs3087258) was performed 
using a polymerase chain reaction (PCR) – based method 
(Hurme and Santtila 1998). A 304-bp PCR fragment of the 
IL-1β promoter region was ampliﬁ  ed using the primer pair 
5′-TGGCATTGATCTGGTTCATC-3′ and 5′-GTTTAG-
GAATCTTCCCACTT-3′. Reaction was performed using 
50 ng genomic DNA, 20 pmol of each primer (Invitrogen), 1 
U Taq polymerase (Fermentas), 0.1 mM dNTP (Fermentas), 
15 mM MgCl2, 60 mM Tris-HCl und 15 mM ammonium-
sulfate. PCR conditions were as follows: 95 °C for 2 min, 
55 °C for 1 min, 74 °C for 1 min, then 38 cycles of 95 °C 
for 1 min, 55 °C for 1 min, 74 °C for 1 min and ﬁ  nally 74 °C 
for 4 min. The products were digested with 6 U of AvaI at 
37 °C for 3h. Fragments were analyzed by electrophoresis 
and stained with ethidium bromide. This gave products that 
either remained intact (IL-1β -511T allele; allele 2) or were 
cut into two fragments of 190 and 114 bp (IL1β -511C 
allele; allele 1). For the analysis of the pentaallelic VNTR 
within intron 2 of the IL-1Ra gene (Tarlow et al 1993), oli-
gonucleotides 5′-TGGCATTGATCTGGTTCATC-3′ and 
5′-TCCTGGTCTGCAGGTAA-3′ were used as primers in 
PCR. Reaction was performed using 50 ng genomic DNA, 
20 pmol of each primer (Invitrogen), 1 U Taq polymerase 
(Fermentas), 0.1 mM dNTP (Fermentas), 3.5 mM MgCl2, 
60 mM Tris-HCl und 15 mM ammoniumsulfate. PCR condi-
tions were: initial denaturation at 96 °C for 1 min followed 
by 35 cycles at 94 °C for 1 min, 60 °C for 1 min, 70 °C for 
1 min and ﬁ  nally 72 °C for 5 min. The PCR products were 
separated by electrophoresis on 2% agarose gel and visual-
ized by ethidium bromide staining. Allele 1 (four repeats) 
was 410 bp long, allele 2 (two repeats) 240 bp, allele 3 (three 
repeats) 325 bp, and allele 4 (ﬁ  ve repeats) 500 bp.
Data analysis
Data analyses were carried out using SPSS (version 12.0). In 
both treatment groups, clinical and demographic characteris-
tics were compared between genotype groups with one-way 
ANOVA or t-test, when appropriate. Continuous data: Within 
treatment groups, HAMD-17 sum score differences between 
genotype groups across the treatment period were analyzed 
using a mixed-effects model repeated-measures method-
ology (MMRM), as MMRM has been shown to provide 
highly accurate modeling of treatment outcome while 
accounting for nonrandom missing data (Mallinckrodt 
et al 2001, 2003). In this model, we included HAMD-17 
sum scores as dependent variables. The independent vari-
ables time and genotype as well as the interaction time × 
genotype were included as ﬁ  xed effects, cases as random 
effects. Age and gender were included as potential covari-
ates. For this analysis, patients with valid HAMD-17 scores 
for at least two weeks of treament (and baseline) were 
included (IL-1β*paroxetine/IL-1β*mirtazapine: n = 44/48 
patients; IL-1Ra*paroxetine/IL-1Ra*mirtazapine: n = 39/46 
patients). Proportions of missing data (IL-1β*paroxetine/
IL-1β*mirtazapine: 3.4%/3.1%; IL-1Ra*paroxetine/
IL-1Ra*mirtazapine: 3.0%/2.5%) were similar in all ana-
lyzed groups. Additionally, within the intention-to-treat 
(ITT) sample HAMD-17 sum score differences between 
genotype groups were analyzed for each assessment day 
and the individual endpoint with one-way ANOVA or t-test, 
if appropriate. Categorical data: Within the ITT sample, Neuropsychiatric Disease and Treatment 2008:4(1) 272
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differences of time to remission (HAMD-17 sum score 
 7) between genotype groups were calculated applying 
Kaplan-Meier curve analyses (KM) with logrank tests in 
each treatment group separately. “Survival time” was deﬁ  ned 
as the time to ﬁ  rst occurrence of remission or – in case of 
nonremission – as the time of the last observation. Again, age 
and gender were included as potential covariates by means 
of Cox regression analysis. Additionally, we determined 
remitters and nonremitters for each assessment day and the 
individual endpoint. The division by genotype led to clear 
2 × 2 contingency tables which were analyzed by Chi-square 
test. The level of signiﬁ  cance was set at 0.05 (two-tailed). A 
correction for multiple testing was not performed because of 
the exploratory nature of the study.
Results
One-hundred-and-sixteen patients gave written informed 
consent. Of the 116 patients, n = 12 patients had to be 
excluded because of missing HAMD-17 data at baseline. 
Considering the data for IL-1β C-511T analysis, n = 3 
patients had to be excluded because of failed genotyping. In 
the case of the IL-1Ra (86bp)n polymorphism, n = 4 patients 
had to be excluded because of failed genotyping. Almost all 
patients were IL-1Ra∗1 or IL-1Ra∗2 allele carriers. In order 
to minimize the chances of spurious associations with very 
rare alleles, subjects bearing any of the other alleles (n = 6) 
were excluded from the analysis. Therefore, the total numbers 
of patients in the ITT samples differ between the analysis 
of the IL-1β (n = 101; females/males: n = 74/27) and the 
IL-1Ra polymorphism (n = 94; females/males: n = 73/21). 
With the exception of a lower proportion of females in the 
group of patients without genotyping (sex ratio f/m = 1.4 
vs. 2.9, p   0.01), patients with or without genotyping were 
structurally similar with regard to age, depression severity 
at baseline and response to double-blind treatment in the 
trial (age, HAMD-17 sum score at baseline, day 42 and at 
endpoint, remitter rates at d42 and at endpoint: p   0.1 for 
each analysis).
Genotype distribution, clinical 
and demographic data
The genotype distributions of IL-1β C-511T and IL-1Ra 
(86bp)n polymorphisms in our sample as well as clinical and 
demographic characteristics are shown in Table 1.
Genotype frequencies of the two analyzed polymorphisms 
showed no deviation from Hardy-Weinberg equilibrium in 
both treatment groups. Genotype frequencies of both SNPs 
did not differ between treatment groups. In paroxetine-treated 
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patients there were no signiﬁ  cant differences among the three 
genotype groups of both polymorphisms in mean age, baseline 
mean HAMD-17 score or mean daily drug dose (p   0.05 for 
each analysis). In mirtazapine-treated patients there were no 
signiﬁ  cant differences of the same clinical and demographi-
cal data (p   0.05 for each analysis), with the exception of 
younger IL-1β-511TT-carriers compared with -511CC- and 
-511CT- bearing patients (F(2) = 3.3; p = 0.045).
IL-1β C-511T polymorphism
Paroxetine-treated patients homozygous for the IL-1β-511T 
allele displayed a more pronounced response during the course 
of treatment than IL-1β-511CT- or -511CC-carriers (data not 
shown). Therefore, IL-1β-511CT- and -511CC-carriers were 
pooled together for further analysis (-511CT/CC). The mean 
values of the HAMD-17 sum scores divided by genotype 
groups (-511TT and -511CT/CC) are plotted in Figure 1.
The global comparison of HAMD-17 score changes 
across the course of treatment showed no clear genotype 
effect (MMRM: F (1,54.6) = 3.4, p = 0.072), but a signiﬁ  cant 
interaction of time × genotype (MMRM: F (5,136.8) = 2.9, p = 
0.017). Neither age (main effect: F (1,59.1) = 0.2, p = 0.68) 
nor gender (main effect: F (1,54.1) = 0.3, p = 0.62; all inter-
actions p   0.05) had a signiﬁ  cant impact on these results 
and were hence omitted as factors in the ﬁ  nal model. Mean 
HAMD-17 scores at particular time points were lower in 
-511TT- compared with -511CT/CC-bearing patients from 
day 14 onwards with statistically signiﬁ  cant differences on 
day 21 (t (41) = 2.3, p = 0.028) and day 28 (t (39) = 2.3, 
p = 0.025) as well as nonsigniﬁ  cant differences on day 
42 (6.2 ± 4.7 vs. 10.4 ± 6.4) and at the endpoint (5.5 ± 4.5 vs. 
11.7 ± 7.2). Mean time to remission (± SE) was signiﬁ  cantly 
shorter in the -511TT-group (29 ± 6 days) compared with the 
-511CT/CC-group (36 ± 2 days) (KM: logrank-test χ2
1 = 4.08; 
p = 0.043). In Cox regression analysis, age (main effect: 
p = 0.98) and gender (main effect: p = 0.81; all interactions 
p   0.1) did not show a statistically signiﬁ  cant effect on these 
results and were thus not included as potential confounders 
in the ﬁ  nal model. Remitter rates were continuously higher in 
-511TT- compared with -511CT/CC- bearing patients from 
day 14 onwards (day 14: 33.3 vs. 13.2%) with signiﬁ  cant 
differences on day 21 (50.0 vs. 10.8%; Pearsons’s χ2
1 = 5.82, 
p = 0.016) and at the endpoint (83.3 vs. 32.5%; χ2
1 = 5.66; 
p = 0.017) as well as nonsigniﬁ  cant differences on day 28 
(50.0 vs. 20.0%) and day 42 (80.0 vs. 35.3%).
The course of mean HAMD-17 scores across the study 
period in mirtazapine-treated patients stratiﬁ  ed by IL-1β 
C-511T genotype groups is depicted in Figure 2.
Between genotype groups, there were neither signiﬁ  cant 
differences of HAMD-17 score changes over the treatment 
period (covariate age: F (1,54.2) = 0.3, p = 0.59; covariate 
gender: F (1,55.5) = 0.9, p = 0.36; all interactions p   0.1) 
nor on particular assessment points (p   0.05 for each analy-
sis). Mean times to remission (± SE) were similar in both 
-511TT- (33 ± 6 days) and -511CT/CC-patients (32 ± 2 days; 
p   0.05) without signiﬁ  cant effects of age (p = 0.65) and 
gender (p = 0.67; all interactions p   0.1) in Cox regression 
analysis. Proportions of remitters of both genotype groups 
did not differ signiﬁ  cantly at any assessment day of the study 
(p   0.05 for each analysis).
IL-1Ra (86bp)n polymorphism
A possible impact of the IL-1Ra (86bp)n polymorphism on 
different treatment response characteristics to paroxetine and 
mirtazapine was analyzed analogously to the analysis of the 
IL-1β C-511T SNP. There were neither clinically meaning-
ful nor statistically signiﬁ  cant differences between the three 
genotype groups IL-1Ra*11, IL-1Ra*12 and IL-1Ra*22 in 
any analyzed outcome measure (p   0.05 for each analysis) 
in paroxetine as well as in mirtazapine-treated patients.
Discussion
Our results provide further suggestive evidence that the IL-1β 
C-511T gene variant affects the response to SSRI treatment 
in patients suffering from major depression. This conclusion 
is derived from the ﬁ  nding that paroxetine-treated patients 
Figure 1 Time course of changes in mean HAMD-17 sum score during treat-
ment in paroxetine-treated patients stratiﬁ  ed by IL-1β C-511T genotype groups. 
∗ = p   0.05.
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with the IL-1β-511TT genotype showed a faster and more 
pronounced response to paroxetine than patients carrying the 
IL-1β-511CT or -511CC genotype. Our ﬁ  nding is in line with 
the report from Yu and colleagues (2003), who also reported 
an advantageous outcome in IL-1β-511TT-patients to ﬂ  uox-
etine treatment for 4 weeks. The mechanisms responsible for 
the observed differences in SSRI antidepressant response are 
not yet established. On the molecular genetic level the effects 
of the IL-1β-511 SNP may be mediated by strong linkage dis-
equilibrium with a TATA box polymorphism at position -31 
from the starting sequence of the IL-1β gene affecting pro-
tein (presumably transcription factors) binding to DNA 
(El-Omar et al 2000). Neurobiologically, one could have 
expected that subjects carrying the more active IL-1β -511TT 
genotype are more resistant to antidepressant treatment. 
However, this was neither the case in the sample studied by 
Yu et al (2003) nor in our sample. An explanation might be 
related to higher levels of IL-1β in -511TT carrying patients 
compared to IL-1β-511C carriers. If some of the effect of 
SSRIs is to diminish the production of central or peripheral 
proinﬂ  ammatory cytokines such as IL-1 (Yirmiya et al 2001; 
Castanon et al 2004; Obuchowicz et al 2006) the response to 
SSRIs could indeed be greater in IL-1β-511TT carriers.
In contrast, we found no associaton between the IL-1β 
C-511T gene variant and mirtazapine treatment response. 
This might be related to different immuno-modulatory 
effects of mirtazapine treatment on IL-1β. Given that, in 
contrast to SSRI, mirtazapine treatment was associated with 
the upregulation of the pro-inﬂ  ammatory tumor necrosis 
factor-α (TNF-α) (Kraus et al 2002; Kast 2003), different 
effects on IL-1β seem possible. However, the multiplicity 
of possible mechanisms of immune modulation by antide-
pressants (Schiepers et al 2005) suggests that several other 
reasons might be involved.
Additionally, we did not ﬁ  nd an association of the IL-1Ra 
(86bp)n intron 2 polymorphism with antidepressant response 
to paroxetine and mirtazapine. This result does not support 
the hypothesis that the IL-1Ra intron 2 VNTR is involved 
in a mechanism affecting treatment outcome to paroxetine 
and mirtazapine. This ﬁ  nding is in line with the results from 
Kubera and colleagues (2000), who reported that IL-1Ra was 
elevated in depressed patients and did not normalize after 
response following antidepressant treatment. Thus, based 
on the available data, it can not be suggested that IL-1Ra is 
involved in neurobiological mechanisms underlying antide-
pressant treatment response. However, if the IL-1Ra gene 
is an uncommon locus affecting antidepressant treatment 
response or one with relatively modest effects, our power 
to detect its effects could have been too small.
The herein reported results are preliminary due to some 
limitations. There were some differences in gender distribution 
between the groups of non-genotyped and genotyped patients. 
However, a selective sample selection is improbable because 
our sample of genotyped patients with more females than 
males is comparable with many other patient samples in similar 
investigations and we did not found gender effects on treatment 
outcome. The small sample size did not allow us to control 
for unknown population stratiﬁ  cation (eg, center effects) and 
possible inﬂ  uences of comorbid personality disorders. The 
exclusion criteria may further limit the generalizability of 
our ﬁ  ndings. We did no correction for multiple testing for the 
obtained p-values. A Bonferroni correction for multiple testing 
(15 tests in each group) would lead to a corrected threshold 
of about 0.003 at the 5% signiﬁ  cance level. If we perform 
Bonferroni correction for multiple testing in this exploratory 
study, all differences are nonsigniﬁ  cant, and thus the results 
must be interpreted with caution. The sample size is small 
for a genetic study examining the relationship between six 
genotypes per group, two polymorphisms and the treatment 
response. Feasible sample sizes in clinical studies are often too 
small to identify genetic variations that would withstand cor-
rection for multiple testing, unless they conferred major effects. 
However, this is very unlikely to be the case in phenotypes of 
complex inheritance where several interacting genes of small 
effect are predicted to contribute to antidepressant response. 
To circumvent this dilemma, replications ideally in larger 
samples will be needed to conﬁ  rm the association.
Figure 2 Time course of changes in mean HAMD-17 sum score during treatment 
in mirtazapine-treated patients stratiﬁ  ed by IL-1β C-511T genotype groups.
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IL-1β and IL-1Ra gene variants and antidepressant treatment response
In conclusion, our results provide further suggestive 
evidence that the IL-1β-511TT genotype is associated with 
an advantageous SSRI treatment response compared with the 
IL-1β-511CT/CC genotype, which is in line with previous 
yet hitherto unreplicated ﬁ  ndings (Yu et al 2003). Differences 
in the mechanisms of action of paroxetine and mirtazapine 
may account for the divergent effects of the IL-1β C-511T 
gene variant on treatment outcome with these substances. 
Our results do not support the hypothesis that the IL-1Ra 
(86bp)n intron 2 VNTR is involved in treatment response 
to paroxetine or mirtazapine in major depression. Replica-
tions in large scale studies, which address the limitations of 
our study, are needed to further clarify the role of the IL-1β 
C-511T variant on SSRI treatment response. If replicated, the 
IL-1β C-511T promoter polymorphism could be considered 
useful for prospective conﬁ  rmatory pharmacogenetic trials 
in patients with major depression.
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